Specific Cell-Permeable Inhibitor of Proteasome Trypsin-like Sites Selectively Sensitizes Myeloma Cells to Bortezomib and Carfilzomib

Department of Pharmacology and Toxicology, Dartmouth Medical School, Dartmouth College, Lebanon, NH 03756, USA.
Chemistry & biology (Impact Factor: 6.65). 05/2011; 18(5):608-18. DOI: 10.1016/j.chembiol.2011.02.015
Source: PubMed


Proteasomes degrade the majority of proteins in mammalian cells, are involved in the regulation of multiple physiological functions, and are established targets of anticancer drugs. The proteasome has three types of active sites. Chymotrypsin-like sites are the most important for protein breakdown and have long been considered the only suitable targets for antineoplastic drugs; however, our recent work demonstrated that inhibitors of caspase-like sites sensitize malignant cells to inhibitors of the chymotrypsin-like sites. Here, we describe the development of specific cell-permeable inhibitors and an activity-based probe of the trypsin-like sites. These compounds selectively sensitize multiple myeloma cells to inhibitors of the chymotrypsin-like sites, including antimyeloma agents bortezomib and carfilzomib. Thus, trypsin-like sites are cotargets for anticancers drugs. Together with inhibitors of chymotrypsin- and caspase-like sites developed earlier, we provide the scientific community with a complete set of tools to separately modulate proteasome active sites in living cells.

Download full-text


Available from: Martijn Verdoes, Aug 04, 2014
1 Follower
127 Reads
  • Source
    • "Interestingly, while close to full inhibition of the b5 subunit in the host cell only has a small effect on viability (Figure 5B), inhibition of this same activity of the parasite proteasome directly correlates with a decrease in P. falciparum growth (Figures 5C and 5E). Furthermore , in agreement with recent data suggesting that inhibition of multiple proteasome activity sites is required to induce cell killing of mammalian cells (Britton et al., 2009; Mirabella et al., 2011), we find that a decrease in HFF viability correlates with inhibition of all three active subunits in the host cell (Figure 5D; see also Figure S5). Therefore, the window of therapy observed for PR3 is likely due to the fact that PR3 is unable to inhibit all of the host proteasome subunits. "
    [Show abstract] [Hide abstract]
    ABSTRACT: The Plasmodium proteasome has been suggested to be a potential antimalarial drug target; however, toxicity of inhibitors has prevented validation of this enzyme in vivo. We report a screen of a library of 670 analogs of the recent US Food and Drug Administration-approved inhibitor, carfilzomib, to identify compounds that selectively kill parasites. We identified one compound, PR3, that has significant parasite killing activity in vitro but dramatically reduced toxicity in host cells. We found that this parasite-specific toxicity is not due to selective targeting of the Plasmodium proteasome over the host proteasome, but instead is due to a lack of activity against one of the human proteasome subunits. Subsequently, we used PR3 to significantly reduce parasite load in Plasmodium berghei infected mice without host toxicity, thus validating the proteasome as a viable antimalarial drug target.
    Chemistry & biology 11/2012; 19(12). DOI:10.1016/j.chembiol.2012.09.019 · 6.65 Impact Factor
  • Source
    • "4 5, 5i CT-like irreversible [105] 5 5, 1i CT-like reversible [140] 6 All All irreversible [141] 7 1, 1i C-like irreversible [142] 8 2 T-like irreversible [143] 9 5, 5i CT-like irreversible [142] O OH O O OH O O HO H H O 25 Withaferin 26 Celastrol R H N H N N H O O O O O R = OtBu N H N H H N N H R O O O O O O R = OtBu, NHBn N R 1 NH 2 O OH R 2 27 Urea-containig peptide Epoxyketones 6 Current Pharmaceutical Design, 2013, Vol. 19, No. 00 Bellavista et al. (Table 2) Contd…. Structure Selectivity Inhibition Mechanism References 10 5 CT-like reversible [144] [145] [146] [147] "
    [Show abstract] [Hide abstract]
    ABSTRACT: Immunoproteasome is an emerging biological target that constitutes a key element not only in antigen presentation but also in T cell and cytokine regulation as well as cellular homeostasis. Its inducible expression and different sensitivity, respect to standard proteasome, towards activity modulators renders it a potential therapeutic target for tumours and central nervous system diseases. In this review we report the cutting edge studies for understanding when immunoproteasome expression is induced and how it regulates pivotal pathways involved in tumours and neuropathologies, including apoptosis and inflammation. We emphasize its role as a new pharmacological target by describing the recent medicinal chemistry efforts aimed at design selective small-molecule modulators of both standard- and immuno-proteasome forms. Finally, we also present an in silico model of the human immunoproteasome structure by the major molecular differences with the 20S standard proteasome and discuss the perspective for the design of novel specific small-molecule modulators for the different proteasome isoforms.
    Current pharmaceutical design 09/2012; 19(4). DOI:10.2174/1381612811306040702 · 3.45 Impact Factor
  • Source
    • "YU-102 (Myung et al., 2001), NC-001 (Britton et al., 2009), and LU-001 (van der Linden et al., 2012) inhibit β1 and β1i sites. (C) Inhibitor of the trypsin-like sites (Mirabella et al., 2011). (D) Inhibitors with selectivity for immunoproteasome subunits over their constitutive counterparts and vice versa. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Proteasomes are large, multisubunit proteolytic complexes presenting multiple targets for therapeutic intervention. The 26S proteasome consists of a 20S proteolytic core and one or two 19S regulatory particles. The 20S core contains three types of active sites. Many structurally diverse inhibitors of these active sites, both natural product and synthetic, have been discovered in the last two decades. One, bortezomib, is used clinically for treatment of multiple myeloma, mantle cell lymphoma, and acute allograft rejection. Five more recently developed proteasome inhibitors are in trials for treatment of myeloma and other cancers. Proteasome inhibitors also have activity in animal models of autoimmune and inflammatory diseases, reperfusion injury, promote bone and hair growth, and can potentially be used as anti-infectives. In addition, inhibitors of ATPases and deubiquitinases of 19S regulatory particles have been discovered in the last decade.
    Chemistry & biology 01/2012; 19(1):99-115. DOI:10.1016/j.chembiol.2012.01.003 · 6.65 Impact Factor
Show more